On June 15, the "Future Healthcare Top 100 Awards" cloud ceremony, hosted by Arterial Network, announced the highly anticipated 2022 list. Leveraging its comprehensive strength in independent innovation, product R&D capabilities, and future growth potential, tricision was named to the 2022 Future Healthcare Top 100 Value Sector List.

The conference, themed "China Stories," analyzed healthcare industry trends from five dimensions: policy direction, technological frontiers, capital perspectives, industrial innovation, and market demand—driving transformative change in the innovative health industry.

Launched in December 2021, the award selection process involved investor interviews, journalist interviews, and industry report analysis. Based on capital attention, supplemented by media focus, annual healthcare enterprise performance data, and future industry development sentiment, the selection covered 60+ segments across four major tracks: medical devices, biopharmaceuticals, digital health, and medical services. The top ten value sectors were identified, with the most representative and growth-oriented innovative companies selected in each.

After over four months of solicit and evaluation of nearly 1,300 company submissions, the final list represents the future of China's medical innovation. As a biopharmaceutical enterprise dedicated to mRNA drug technology innovation and product development, tricision adheres to the philosophy of "people-oriented, technology for good, innovation-driven, and future-leading." The Company has established a core technology platform of "One Body" (mRNA nucleic acid technology) and "Two Wings" (nanodelivery and cell delivery systems) , achieving breakthroughs in mRNA functional modification, LNP lyophilization, and DC cell loading—forming an integrated R&D-to-production technology system to advance mRNA nucleic acid drug innovation, manufacturing translation, and clinical application.